Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1b Study Evaluating the Safety and Tolerability of CLB-4000 with or without Peg-IFNa-2a in Subjects with Chronic Hepatitis B: non-randomised cohorts

Next Previous
Trial Profile

A Phase 1b Study Evaluating the Safety and Tolerability of CLB-4000 with or without Peg-IFNa-2a in Subjects with Chronic Hepatitis B: non-randomised cohorts

Status: Not yet recruiting
Phase of Trial: Phase I

Latest Information Update: 24 Nov 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs CLB 4000 (Primary) ; Peginterferon alfa-2a
  • Indications Hepatitis B
  • Focus Adverse reactions; First in man

Most Recent Events

  • 24 Nov 2025 New trial record
  • 15 Oct 2025 According to ClearB Therapeutics media release, review of the safety data from the sentinel subject supported enrollment for the remainder of the cohort in their Phase 1b clinical study evaluating the therapeutic vaccine CLB-4000 (ACTRN12625000250437 and ACTRN12625000204448). Results are expected on a rolling basis starting 2H 2026.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top